- Home
- RRBI vs PHAT Comparison
RRBI vs PHAT Comparison
Compare RRBI & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRBI | PHAT |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.3M | 942.6M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RRBI | PHAT |
|---|---|---|
| Price | $73.99 | $14.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $67.00 | $17.33 |
| AVG Volume (30 Days) | 34.0K | ★ 777.9K |
| Earning Date | 01-29-2026 | 10-30-2025 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | ★ 26.56 | N/A |
| EPS | ★ 6.01 | N/A |
| Revenue | $118,909,000.00 | ★ $147,190,000.00 |
| Revenue This Year | $7.10 | $218.59 |
| Revenue Next Year | N/A | $84.38 |
| P/E Ratio | $12.31 | ★ N/A |
| Revenue Growth | 11.93 | ★ 460.30 |
| 52 Week Low | $46.33 | $2.21 |
| 52 Week High | $76.13 | $16.45 |
Technical Indicators
Market Signals| Indicator | RRBI | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 69.73 | 53.40 |
| Support Level | $69.94 | $14.12 |
| Resistance Level | $72.68 | $16.27 |
| Average True Range (ATR) | 1.89 | 0.74 |
| MACD | 0.46 | -0.11 |
| Stochastic Oscillator | 86.73 | 23.18 |
Price Performance
Historical ComparisonAbout RRBI Red River Bancshares Inc.
Red River Bancshares Inc is the bank holding company for the red river bank. The principal business of the Bank is lending and accepting deposits from businesses, professionals, individuals, and public entities. The bank's primary deposit products are demand deposits, savings deposits, and time deposits. The bank maintains a diversified loan portfolio with a focus on commercial real estate (Owner Occupied and Non-Owner Occupied), one-to-four-family residential, commercial, and industrial loans, construction and development Loans, and others. also, provides Treasury Management Services, Private Banking Services, Brokerage Services, and Other Banking Services.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.